Dementia Education Program Newsletter
Management of Disease Modifying Interventions in Alzheimer's
This workshop will serve to discuss the indications and, prescription, and management of adverse events associated with anti-amyloid therapy with monoclonal anti-bodies.
Suzanne Schindler, MD, PhD
Department of Neurology, Washington University School of Medicine
°Õ²¹±ô°ì:ÌýBiomarkers for Detection of AD and Indications of Anti-Amyloid Therapy
Abstract: TBD
Alireza Atri, MD, PhD
Department of Neurology, Harvard Medical School
°Õ²¹±ô°ì:ÌýAmyloid Related Imaging Abnormalities (ARIA)
Abstract: TBD
Ìý
Programme
Tuesday, December 3, 2024
13:00 |
Welcome &ÌýOpening Remarks Pedro Rosa-Neto, MD, PhD, The Douglas Research Centre, À¦°óSMÉçÇø Moderator:ÌýSerge Gauthier, MD,ÌýThe Douglas Research Centre, À¦°óSMÉçÇø |
13:10 |
Disease Modify Interventions in AD in Canada TBA |
14:00 |
Biomarkers for Detection of AD and Indications of Anti-Amyloid Therapy Suzanne Schindler, MD, PhD,ÌýKnight Alzheimer Disease Research Center,ÌýWashington University School of Medicine in St. Louis |
14:45 | Refreshment Pause |
15:15 |
Amyloid Related Imaging Abnormalities (ARIA) Alireza Atri, MD, PhD,ÌýBanner Sun Health Research Institute,ÌýHarvard Medical School |
16:00 |
Closing Remarks Pedro Rosa-Neto, MD, PhD, The Douglas Research Centre, À¦°óSMÉçÇø |
16:15 | Cocktail & Networking |
Sponsors
Organizing Committee
Pedro Rosa-Neto
Director, Translational Neuroimaging Laboratory, Douglas Research Centre
Debbie Rashcovsky
Neuro Events Team Lead